Wednesday, August 15, 2018

The Next Frontier in Cancer Care

Value has become a central topic in any debate regarding cancer care in Greece and abroad, for a simple reason: reality has caught up with us. Costs and treatment innovations are conflicting realities that force the oncology community to adopt value-based solutions to a system in crisis. On one side, the pace of innovation in oncology is tremendous and unprecedented: newly approved drugs abound; precision oncology and immunotherapy are gradually becoming a reality; and patients are having access to an increasing number of treatment options that help them live longer with better quality of life. On the other side, the costs to treat cancer are astronomical and continue to increase, threatening our own ability to provide cancer care and causing financial harm to patients.

Early Bird

Scientific Committee

President

  • Odysseas Zoras, MD, PhD FACS, Rector of the University of Crete, Professor in Surgical Oncology, University of Crete, Medical School, Head of the Department of Surgical Oncology, University Hospital of Heraklion, Member of the BoD of the European Society of Surgical Oncology (ESSO), Past President of the Hellenic Society of Surgical Oncology (HSSO)

Honorary President

  • Othon Iliopoulos, Associate Professor of Medicine, Harvard Medical School, Member of the Hellenic National Council of Research and Innovation (ΕΣΕΚ)

Members

  • Ioannis Boukovinas, MD, PhD, PharmaD, Medical Oncologist, Head of Oncology Unit, “Bioclinic”, Thessaloniki, Greece, President of the Hellenic Society of Medical Oncology (HeSMO)
  • Maria Gazouli, PhD, Associate Professor of Molecular Biology, Medical School, National and Kapodistrian University of Athens
  • Zoe Grammatoglou, President of the Hellenic Association of Cancer Patients K.E.F.I. of Athens
  • George Kapetanakis, Secretary, The Hellenic Cancer Federation – ELLOK
  • Paris Kosmidis, Medical Oncologist at Hygeia Hospital, past ESMO President
  • Zenia Saridaki-Zoras, MD, PhD Medical Oncologist, Scientific Director of the Oncology Department “Asklepios”, Member of the Board of Directors of the Hellenic Society of Medical Oncology
  • Konstantinos N. Syrigos, MD, PhD, FCCP, Professor of Medicine & Medical Oncology, Head, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, National & Kapodistrian University, Adj. Professor of Medicine, Pittsburgh School of Medicine, USA, Vis. Professor of Thoracic Oncology, Yale School of Medicine, USA

Conference’s Scope

The conference, now in its fourth year, is a forum for discussion for government representatives, academic society, physicians, patients, researchers, and pharmaceutical industry executives, to discuss innovative therapeutic approaches and cost-effective measures to the benefit of healthcare system and patients. The scope of the conference is to explore opportunities for greater multi-stakeholder cooperation and a more integrated approach to cancer care as key drivers to deliver sustainable and high-value care for patients. Best practices at a national and international level will contribute to the dialogue aiming at significantly improving cancer patient outcomes, fostering innovative research approaches, intensifying cancer prevention research efforts, and reducing the financial burden targeted to this disease.

This year the special theme of the conference is the next frontier in cancer care that aims to showcase the most innovative methods of treatment, while at the same time confronting the urgency to balance the delivery of high quality cancer care with costs. Cancer & Personalized Medicine Conference will offer a platform to discuss new models of care delivery and reimbursement that emphasize value.

Key Issues

  • Cancer Policies and the Cost of Precenting, Researching and Treating Cancer
  • Innovation in Cancer Research & Treatment
  • Personalised and Targeted Therapies & the Use of Biomarkers
View more

Keynote Speaker

Stephen Palmer Stephen Palmer is a Professor and Deputy Director of TEEHTA. He has worked in economic evaluation for over 15 years in areas including pharmaceuticals, cardiology, cancer, mental health, diagnostic and screening programmes and policy. He has extensive experience of health economic evaluation, regulatory and reimbursement processes.

Speakers & Coordinators

  • Kathy Apostolidis, President - Hellenic Cancer Federation-ELL.O.K., Vice President of ECPC-European Cancer Patient Coalition
  • Ioannis Boukovinas, MD, PhD, Medical Oncologist, Head of Oncology Unit, “Bioclinic”, Thessaloniki, Greece, President of the Hellenic Society of Medical Oncology (HeSMO)
  • Maria Gazouli, PhD Associate Professor of Molecular Biology, Medical School, National & Kapodistrian University of Athens
  • Ioanna Michalopoulou , Lawyer, LL.M. Managing Partner at Michalopoulou & Associates Law Group
  • George Pentheroudakis, MD Associate Professor of Oncology, Department of Medical Oncology, Medical School, University of Ioannina
  • Zenia Saridaki-Zoras, MD, PhD Medical Oncologist, Scientific Director of the Oncology Department “Asklepios”, Member of the Board of Directors of the Hellenic Society of Medical Oncology
  • Konstantinos N. Syrigos, MD, PhD, FCCP, Professor of Medicine & Medical Oncology, Head, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, National & Kapodistrian University, Adj. Professor of Medicine, Pittsburgh School of Medicine, USA, Vis. Professor of Thoracic Oncology, Yale School of Medicine, USA
  • Dimitris Thanos, Adjunct Professor, Department of Biochemistry and Molecular Biophysics, College of Physicians & Surgeons, Columbia University, Director of the Center of Basic Research and Chairman of the Scientific Board, Biomedical Research Foundation of the Academy of Athens
  • Odysseas Zoras, MD, PhD FACS, Rector of the University of Crete, Professor in Surgical Oncology, University of Crete, Medical School, Head of the Department of Surgical Oncology, University Hospital of Heraklion, Member of the BoD of the European Society of Surgical Oncology (ESSO), Past President of the Hellenic Society of Surgical Oncology (HSSO)

Who should attend

  • Government representatives
  • National health system regulators and administrators
  • Academic Society
  • Consultants
  • Researchers
  • Radiologists
  • Chemotherapists
  • Pathologists
  • Patient Advocates and Patient Groups
  • Healthcare Industry representatives (Pharmaceutical Companies, Medical Devices Manufacturing Companies, Diagnostics Companies)
  • Students
  • Journalists

  • ORGANIZED BY
  • SPONSOR

© 2018 Boussias Communications, all rights reserved. info@boussias.com, T:210 6617777, F:210 6617778

Designed by Boussias
New Media Team